Shikhar Mehrotra to Neoplasms
This is a "connection" page, showing publications Shikhar Mehrotra has written about Neoplasms.
Connection Strength
1.810
-
New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy. Cells. 2022 02 17; 11(4).
Score: 0.377
-
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metab. 2018 01 09; 27(1):85-100.e8.
Score: 0.280
-
Reducing CD73 expression by IL1?-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 2014 Nov 01; 74(21):6048-59.
Score: 0.225
-
Promoting thiol expression increases the durability of antitumor T-cell functions. Cancer Res. 2014 Nov 01; 74(21):6036-6047.
Score: 0.224
-
Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv Cancer Res. 2009; 102:197-227.
Score: 0.152
-
Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8+ T Cells. Cancer Res. 2022 07 18; 82(14):2640-2655.
Score: 0.097
-
HuR as a molecular target for cancer therapeutics and immune-related disorders. Adv Drug Deliv Rev. 2022 09; 188:114442.
Score: 0.097
-
Identification of human CD4+ T cell populations with distinct antitumor activity. Sci Adv. 2020 07; 6(27).
Score: 0.084
-
CD38-NAD+-Sirt1 axis in T cell immunotherapy. Aging (Albany NY). 2019 10 23; 11(20):8743-8744.
Score: 0.080
-
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Front Immunol. 2018; 9:1740.
Score: 0.074
-
IL-2 and Beyond in Cancer Immunotherapy. J Interferon Cytokine Res. 2018 02; 38(2):45-68.
Score: 0.071
-
Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal. 2013 Apr 20; 18(12):1497-534.
Score: 0.049